查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1892699

植入式药物输送帮浦市场机会、成长驱动因素、产业趋势分析及预测（2025-2034年）

Implantable Drug Delivery Pump Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球植入式药物输送帮浦市值为 7,910 万美元，预计到 2034 年将以 8.3% 的复合年增长率成长至 1.73 亿美元。

植入式药物输送帮浦市场 - IMG1

慢性疼痛、痉挛和其他长期疾病的日益普遍，推动了对先进植入式帮浦的需求，这些帮浦能够确保药物的可控和持续输送。医院、专科诊所和门诊手术中心正越来越多地采用这些系统，以改善患者预后、更有效地管理慢性疾病并提高营运效率。市面上提供可编程和恆速泵，可提供精准的标靶治疗，减少全身副作用并提高患者依从性。包括小型化帮浦设计、生物相容性3D列印组件、无线遥测和远端病患监测在内的技术进步，正在提升设备的功能性、安全性和便利性，加速临床应用，并促进其在全球慢性疾病管理中的更广泛应用。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 7910万美元
预测值 1.73亿美元
复合年增长率 8.3%

2024年，可程式植入式药物输注帮浦市占率达91.8%。这类帮浦因其能够提供个人化、精准且可控的药物输注而备受青睐。临床医生可以根据患者的反应、疾病进展和治疗需求调整剂量，从而在改善疗效的同时最大限度地减少不良反应。这种灵活性使得可程式泵成为需要持续、精准给药的慢性病治疗的关键。

2024 年，慢性疼痛管理领域占市场份额的 52.7%，预计在 2025 年至 2034 年间将达到 8,790 万美元。神经性疼痛、肌肉骨骼疼痛和术后疼痛病例的增加推动了需求，因为植入式帮浦可以直接有效地输送镇痛药，与口服或全身性治疗相比，可确保快速起效并提高治疗效果。

2024年，北美植入式药物输送帮浦市占率预计将达到61.8%，主要得益于先进的医疗基础设施、完善的健保报销系统以及对创新医疗技术的早期应用。该地区慢性病高发以及微创疗法日益受到青睐，推动了医院和专科诊所对药物输送泵的采用。美国FDA和加拿大卫生部推出的有利监管政策也进一步促进了药物输送泵的快速商业化和创新。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

  • 产业生态系分析
  • 产业影响因素
    • 成长驱动因素
      • 慢性疼痛、痉挛和癌症的盛行率不断上升
      • 标靶和可控药物传递的优势
      • 泵浦设计方面的技术进步
      • 人们越来越倾向选择微创疗法
    • 产业陷阱与挑战
      • 高昂的设备和植入成本
      • 设备故障和感染的风险
    • 市场机会
      • 物联网与远端监控的集成
      • 对个人化医疗的需求日益增长
  • 成长潜力分析
  • 监管环境
    • 北美洲
    • 欧洲
    • 亚太地区
  • 技术进步
    • 当前技术趋势
      • 微型植入式帮浦
      • 可编程且对病人友善的输液系统
      • 微创植入技术
    • 新兴技术
      • 配备人工智慧加药演算法的智慧泵
      • 无线连接和远端监控
      • 整合安全和警报系统
  • 差距分析
  • 波特的分析
  • PESTEL 分析
  • 未来市场趋势
    • 人工智慧、数位医疗和互联输液系统的整合
    • 联合药物-器械疗法的开发
    • 随着新兴市场医疗基础设施的改善，其成长势头强劲。

第四章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 竞争定位矩阵
  • 主要市场参与者的竞争分析
  • 关键进展
    • 併购
    • 合作伙伴关係与合作
    • 新产品发布
    • 扩张计划

第五章：市场估算与预测：依产品类型划分，2021-2034年

  • 可编程植入式药物输送泵
  • 恆速（固定流量）植入式泵

第六章：市场估算与预测：依应用领域划分，2021-2034年

  • 慢性疼痛管理
  • 痉挛管理
  • 肿瘤/化疗
  • 其他慢性疾病

第七章：市场估算与预测：依最终用途划分，2021-2034年

  • 医院
  • 门诊手术中心
  • 其他最终用途

第八章：市场估算与预测：依地区划分，2021-2034年

  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 排

第九章：公司简介

  • Boston Scientific (Integra Oncology)
  • Infusyn Therapeutics
  • Medtronic
  • Tricumed Medizintechnik
简介目录
Product Code: 15372

The Global Implantable Drug Delivery Pump Market was valued at USD 79.1 million in 2024 and is estimated to grow at a CAGR of 8.3% to reach USD 173 million by 2034.

Implantable Drug Delivery Pump Market - IMG1

The rising prevalence of chronic pain, spasticity, and other long-term disorders is driving demand for advanced implantable pumps that ensure controlled and sustained drug delivery. Hospitals, specialty clinics, and ambulatory surgical centers are increasingly adopting these systems to enhance patient outcomes, manage chronic conditions more effectively, and improve operational efficiency. The market offers programmable and constant-rate pumps that provide precise, targeted therapy, reducing systemic side effects and improving adherence. Technological advancements, including miniaturized pump designs, biocompatible 3D-printed components, wireless telemetry, and remote patient monitoring, are enhancing device functionality, safety, and convenience, accelerating clinical adoption and encouraging broader use in chronic disease management globally.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$79.1 Million
Forecast Value$173 Million
CAGR8.3%

The programmable implantable drug delivery pumps segment held 91.8% share in 2024. These pumps are favored due to their ability to provide personalized, precise, and controlled drug administration. Clinicians can adjust dosages based on patient response, disease progression, and therapy needs, improving outcomes while minimizing adverse effects. This flexibility makes programmable pumps essential for chronic conditions requiring ongoing, precise medication delivery.

The chronic pain management segment accounted for a 52.7% share in 2024 and is expected to reach USD 87.9 million during 2025-2034. Rising cases of neuropathic, musculoskeletal, and post-surgical pain are fueling demand, as implantable pumps deliver analgesics directly and efficiently, ensuring rapid onset and enhanced therapeutic efficacy compared to oral or systemic treatments.

North America Implantable Drug Delivery Pump Market held a 61.8% share in 2024, supported by advanced healthcare infrastructure, strong reimbursement systems, and early adoption of innovative medical technologies. The high prevalence of chronic diseases in the region and the growing preference for minimally invasive therapies are driving pump adoption in hospitals and specialty clinics. Favorable regulatory pathways by the U.S. FDA and Health Canada further encourage rapid commercialization and innovation.

Major players operating in the Global Implantable Drug Delivery Pump Market include Medtronic, Infusyn Therapeutics, Boston Scientific (Integra Oncology), and Tricumed Medizintechnik. Companies in the implantable drug delivery pump market are focusing on strategies such as investing heavily in R&D to develop miniaturized, programmable, and remote-monitoring-enabled pumps. Strategic partnerships with hospitals, specialty clinics, and research institutions help expand their distribution networks and clinical adoption. Firms are also emphasizing global market expansion, enhancing regulatory compliance, and implementing targeted marketing strategies to raise awareness among clinicians and patients. Product differentiation through advanced telemetry, wireless communication, and customizable therapy options ensures competitive advantage, while ongoing innovation and service support strengthen brand loyalty and penetration in chronic disease management segments.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product type trends
    • 2.2.3 Application trends
    • 2.2.4 End Use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of chronic pain, spasticity, and cancer
      • 3.2.1.2 Advantages of targeted and controlled drug delivery
      • 3.2.1.3 Technological advancements in pump design
      • 3.2.1.4 Growing preference for minimally invasive therapies
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High device and implantation cost
      • 3.2.2.2 Risk of device malfunction and infection
    • 3.2.3 Market opportunities
      • 3.2.3.1 Integration of IoT and remote monitoring
      • 3.2.3.2 Rising demand for personalized medicine
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technological advancemnets
    • 3.5.1 Current technological trends
      • 3.5.1.1 Miniaturized implantable pumps
      • 3.5.1.2 Programmable and patient-friendly infusion systems
      • 3.5.1.3 Minimally invasive implantation techniques
    • 3.5.2 Emerging technologies
      • 3.5.2.1 Smart pumps with AI-based dosing algorithms
      • 3.5.2.2 Wireless connectivity and remote monitoring
      • 3.5.2.3 Integrated safety and alert systems
  • 3.6 Gap analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Future market trends
    • 3.9.1 Integration of AI, digital health, and connected infusion systems
    • 3.9.2 Development of combination drug-device therapies
    • 3.9.3 Growth in emerging markets with improving healthcare infrastructure

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Competitive analysis of major market players
  • 4.6 Key developments
    • 4.6.1 Mergers & acquisitions
    • 4.6.2 Partnerships & collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Programmable implantable drug delivery pumps
  • 5.3 Constant-rate (Fixed-flow) implantable pumps

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Chronic pain management
  • 6.3 Spasticity management
  • 6.4 Oncology/Chemotherapy
  • 6.5 Other chronic conditions

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Ambulatory surgical centers
  • 7.4 Other End Use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 RoW

Chapter 9 Company Profiles

  • 9.1 Boston Scientific (Integra Oncology)
  • 9.2 Infusyn Therapeutics
  • 9.3 Medtronic
  • 9.4 Tricumed Medizintechnik